Bristol-Myers tries to salvage $74 billion deal with Celgene. Meets with investors in NYC, Boston
March 01, 2019 at 05:00 AM EST
Bristol-Myers Squibb is meeting with shareholders in Boston and New York as its $74 billion purchase of drugmaker Celgene is at risk of being derailed.
